[<sup>18</sup>F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels.

Although no significant differences in clinical indicators were observed between the 5 true-positive and 2 false-positive category 3 lesions, PSAdt showed a nearly significant trend (6.24 vs 16.0 months, P = .052; data not shown), suggesting that a more rapid PSA increase may indicate a greater probability of true-positive findings in equivocal lesions.

also in 3,349 other papers